Plexision Secures $365K Grant to Advance Personalized Transplant Diagnostics and Rejection Risk Prediction

Plexision is thrilled to announce a successful funding round, raising $365,000 to accelerate its pioneering work in personalized diagnostics and drug development for solid organ transplantation and immune-related disorders. This investment marks a significant milestone for Plexision, highlighting industry confidence in its ability to revolutionize patient care through innovative cellular biomarker technology. At the heart of Plexision’s efforts is the patented Pleximmune™ assay, a groundbreaking test designed to predict the risk of transplant rejection by measuring antigen-specific white blood cells using patent-pending technology. By providing a clear and timely assessment of rejection risk, Plexision’s bioassay offers a vital tool for both transplant recipients and drug developers, ensuring that treatment and therapeutic strategies are tailored to each individual patient’s needs. The raised funds will be strategically deployed to further enhance the capabilities of Plexision’s state-of-the-art CLIA-certified central laboratory located in Pittsburgh, where precise and personalized testing is conducted. This investment will empower the company to refine and expand its cell-based testing portfolio, thereby strengthening its position as a leader in personalized medicine for transplant care. Notably, Plexision’s Pleximmune™ blood test is the first of its kind to be offered to children undergoing liver or intestine transplantation, representing a groundbreaking advancement in pediatric transplant diagnostics. As Plexision continues to push boundaries in cellular biomarker research and application, this funding will not only support technological innovation but will also pave the way for more informed clinical decisions, ultimately improving outcomes for patients and setting new standards in transplantation medicine.